Lorvotuzumab mertansine, a CD56-targeting antibody-drug conjugate with potent antitumor activity against small cell lung cancer in human xenograft models

mAbs

Volumn 6, Issue 2, 2014, Pages 556-566

  Whiteman, Kathleen R ^a   Johnson, Holly A ^a   Mayo, Michele F ^a   Audette, Charlene A ^a   Carrigan, Christina N ^a   LaBelle, Alyssa ^a   Zukerberg, Lawrence ^b   Lambert, John M ^a   Lutz, Robert J ^a  

^a IMMUNOGEN INC   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

ADC; Antibody drug conjugate; CD56; Combination therapy; Maytansinoid; Small cell lung cancer; Xenografts

Indexed keywords

CARBOPLATIN; CD56 ANTIGEN; CISPLATIN; ETOPOSIDE; LORVOTUZUMAB MERTANSINE; PACLITAXEL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; DRUG CONJUGATION; HUMAN; HUMAN CELL; IN VITRO STUDY; LOW DRUG DOSE; LUNG SMALL CELL CANCER; MONOTHERAPY; MOUSE; NONHUMAN;

ADC; ANTIBODY-DRUG CONJUGATE; CD56; COMBINATION THERAPY; MAYTANSINOID; SMALL CELL LUNG CANCER; XENOGRAFTS;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIGENS, CD56; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CYTOTOXICITY, IMMUNOLOGIC; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; IMMUNOTHERAPY; LUNG NEOPLASMS; MAYTANSINE; MICE; MICE, SCID; SMALL CELL LUNG CARCINOMA; TUBULIN MODULATORS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84896513302     PISSN: 19420862     EISSN: 19420870     Source Type: Journal    
DOI: 10.4161/mabs.27756     Document Type: Article

References (47)

1. American Cancer Society. ACS, Cancer Facts and Figures 2010. ACS, Cancer Facts and Figures 2010. Atlanta, 2010.
2. Puglisi M, Dolly S, Faria A, Myerson JS, Popat S, O'Brien ME. Treatment options for small cell lung cancer - do we have more choice? Br J Cancer 2010; 102:629-38; PMID:20104223; http://dx.doi.org/10.1038/sj.bjc.6605527
3. Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, Spitznagel EL, Piccirillo J. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 2006; 24:4539-44; PMID:17008692; http://dx.doi.org/10.1200/JCO.2005.04.4859
4. Rosti G, Bevilacqua G, Bidoli P, Portalone L, Santo A, Genestreti G. Small cell lung cancer. Ann Oncol 2006; 17(Suppl 2):ii5-10; PMID:16608983; http://dx.doi.org/10.1093/annonc/mdj910
5. Quoix E. Topotecan in the treatment of relapsed small cell lung cancer. Onco Targets Ther 2008; 1:79-86; PMID:21127755; http://dx.doi.org/10.2147/OTT. S3689
6. Stinchcombe TE, Gore EM. Limited-stage small cell lung cancer: current chemoradiotherapy treatment paradigms. Oncologist 2010; 15:187-95; PMID:20145192; http://dx.doi.org/10.1634/theoncologist.2009-0298
7. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines): Small cell lung cancer, Version 1.2011. National Comprehensive Cancer Network, 2011.
8. Simon GR, Turrisi A. Management of small cell lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). Chest 2007; 132:324S-39S. (Pubitemid 47505212)
9. Rosti G, Carminati O, Monti M, Tamberi S, Marangolo M. Chemotherapy advances in small cell lung cancer. Ann Oncol 2006; 17(Suppl 5):v99-102; PMID:16807475; http://dx.doi.org/10.1093/annonc/mdj961
10. von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, Stewart DJ, Clark PI, Palmer MC, Depierre A, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 1999; 17:658-67; PMID:10080612
11. Chari RV, Martell BA, Gross JL, Cook SB, Shah SA, Blättler WA, McKenzie SJ, Goldmacher VS. Immunoconjugates containing novel maytansinoids: promising anticancer drugs. Cancer Res 1992; 52:127-31; PMID:1727373
12. Remillard S, Rebhun LI, Howie GA, Kupchan SM. Antimitotic activity of the potent tumor inhibitor maytansine. Science 1975; 189:1002-5; PMID:1241159; http://dx.doi.org/10.1126/science.1241159
13. Wang L, Amphlett G, Blättler WA, Lambert JM, Zhang W. Structural characterization of the maytansinoid-monoclonal antibody immunoconjugate, huN901-DM1, by mass spectrometry. Protein Sci 2005; 14:2436-46; PMID:16081651; http://dx.doi.org/10.1110/ps.051478705
14. Griffin JD, Hercend T, Beveridge R, Schlossman SF. Characterization of an antigen expressed by human natural killer cells. J Immunol 1983; 130:2947-51; PMID:6574190
15. Aletsee-Ufrecht MC, Langley K, Rotsch M, Havemann K, Gratzl M. NCAM: a surface marker for human small cell lung cancer cells. FEBS Lett 1990; 267:295-300; PMID:2165922; http://dx.doi.org/10.1016/0014-5793(90)80948-I
16. Rygaard K, Møller C, Bock E, Spang-Thomsen M. Expression of cadherin and NCAM in human small cell lung cancer cell lines and xenografts. Br J Cancer 1992; 65:573-7; PMID:1314069; http://dx.doi.org/10.1038/bjc.1992.116
17. Kibbelaar RE, Moolenaar CE, Michalides RJ, Bitter-Suermann D, Addis BJ, Mooi WJ. Expression of the embryonal neural cell adhesion molecule N-CAM in lung carcinoma. Diagnostic usefulness of monoclonal antibody 735 for the distinction between small cell lung cancer and non-small cell lung cancer. J Pathol 1989; 159:23-8; PMID:2478684; http://dx.doi.org/10.1002/path.1711590108
18. Hida T, Koike K, Sekido Y, Nishida K, Sugiura T, Ariyoshi Y, Takahashi T, Ueda R. Epitope analysis of cluster 1 and NK cell-related monoclonal antibodies. Br J Cancer Suppl 1991; 14:24-8; PMID:1710138
19. Carbone DP, Koros AM, Linnoila RI, Jewett P, Gazdar AF. Neural cell adhesion molecule expression and messenger RNA splicing patterns in lung cancer cell lines are correlated with neuroendocrine phenotype and growth morphology. Cancer Res 1991; 51:6142-9; PMID:1718595
20. Roy DC, Ouellet S, Le Houillier C, Ariniello PD, Perreault C, Lambert JM. Elimination of neuroblastoma and small-cell lung cancer cells with an anti-neural cell adhesion molecule immunotoxin. J Natl Cancer Inst 1996; 88:1136-45; PMID:8757193; http://dx.doi.org/10.1093/jnci/88.16.1136
21. Carrigan C, Xu S, Zhao Y, O'Keefe J, Qin A, O'Leary J, Payne G, Lutz R. The antigen target of IMGN901, CD56, is expressed at significant levels in merkel cell carcinoma (MCC) AACR Annual Meeting. Washington, DC, 2010.
22. Cho EY, Choi Y, Chae SW, Sohn JH, Ahn GH. Immunohistochemical study of the expression of adhesion molecules in ovarian serous neoplasms. Pathol Int 2006; 56:62-70; PMID:16445817; http://dx.doi.org/10.1111/j.1440-1827.2006.01925. x
23. McCluggage WG, McKenna M, McBride HA. CD56 is a sensitive and diagnostically useful immunohistochemical marker of ovarian sex cordstromal tumors. Int J Gynecol Pathol 2007; 26:322-7; PMID:17581419; http://dx.doi.org/ 10.1097/01.pgp.0000236947.59463.87
24. Veras E, Deavers MT, Silva EG, Malpica A. Ovarian nonsmall cell neuroendocrine carcinoma: a clinicopathologic and immunohistochemical study of 11 cases. Am J Surg Pathol 2007; 31:774-82; PMID:17460463; http://dx.doi.org/10. 1097/01.pas.0000213422.53750.d1
25. Tassone P, Gozzini A, Goldmacher V, Shammas MA, Whiteman KR, Carrasco DR, Li C, Allam CK, Venuta S, Anderson KC, et al. In vitro and in vivo activity of the maytansinoid immunoconjugate huN901-N2′-deacetyl-N2′-(3- mercapto-1-oxopropyl)-maytansine against CD56+ multiple myeloma cells. Cancer Res 2004; 64:4629-36; PMID:15231675; http://dx.doi.org/10.1158/0008-5472.CAN-04- 0142
26. Metzgeroth G, Mantz C, Kuhn C, Schultheis B, Hehlmann R, Hastka J. Reliable identification of small cell lung cancer in cytological specimens by immunocytology. Onkologie 2007; 30:311-5; PMID:17551254; http://dx.doi.org/10. 1159/000102145
27. Lantuejoul S, Moro D, Michalides RJ, Brambilla C, Brambilla E. Neural cell adhesion molecules (NCAM) and NCAM-PSA expression in neuroendocrine lung tumors. Am J Surg Pathol 1998; 22:1267-76; PMID:9777989; http://dx.doi.org/10. 1097/00000478-199810000-00012
28. Broers JL, Rot MK, Oostendorp T, Huysmans A, Wagenaar SS, Wiersma-van Tilburg AJ, Vooijs GP, Ramaekers FC. Immunocytochemical detection of human lung cancer heterogeneity using antibodies to epithelial, neuronal, and neuroendocrine antigens. Cancer Res 1987; 47:3225-34; PMID:2438035
29. Roguska MA, Pedersen JT, Henry AH, Searle SM, Roja CM, Avery B, Hoffee M, Cook S, Lambert JM, Blättler WA, et al. A comparison of two murine monoclonal antibodies humanized by CDR-grafting and variable domain resurfacing. Protein Eng 1996; 9:895-904; PMID:8931129; http://dx.doi.org/10.1093/protein/9. 10.895
30. rd, Rugo HS, Vukelja SJ, Vogel CL, Borson RA, Limentani S, Tan-Chiu E, Krop IE, Michaelson RA, Girish S, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011; 29:398-405; PMID:21172893; http://dx.doi.org/10.1200/JCO.2010.29.5865
31. Krop IE, Beeram M, Modi S, Jones SF, Holden SN, Yu W, Girish S, Tibbitts J, Yi JH, Sliwkowski MX, et al. Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 2010; 28:2698-704; PMID:20421541; http://dx.doi.org/10.1200/JCO.2009.26.2071
32. Simon M, Argiris A, Murren JR. Progress in the therapy of small cell lung cancer. Crit Rev Oncol Hematol 2004; 49:119-33; PMID:15012973; http://dx.doi.org/10.1016/S1040-8428(03)00118-5
33. Loehrer PJ Sr., Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, Einhorn LH. Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 1995; 13:2594-9; PMID:7595712
34. Miyamoto H, Nakabayashi T, Isobe H, Akita H, Kawakami Y, Arimoto T, Asakawa M, Suzuki A, Fujikane T, Shimizu T, et al. A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 1992; 49:431-5; PMID:1334539; http://dx.doi.org/10.1159/000227087
35. Yamamoto N, Tsurutani J, Yoshimura N, Asai G, Moriyama A, Nakagawa K, Kudoh S, Takada M, Minato Y, Fukuoka M. Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer. Anticancer Res 2006; 26(1B):777-81; PMID:16739353
36. 2nd, Miller AA, Watson DM, Sandler AB, Kelly K, Marks RS, Perry MC, Ansari RH, Otterson G, et al.; Cancer and Leukemia Group. Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 2005; 23:3752-9; PMID:15923572; http://dx.doi.org/10.1200/JCO.2005. 09.071
37. Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, Kakolyris S, Bania E, Jordanoglou J, Agelidou M, et al.; Greek Lung Cancer Cooperative Group. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 2001; 12:463-70; PMID:11398877; http://dx.doi.org/10.1023/A:1011131303391
38. Lambert JM. Antibody-maytansinoid conjugates: A new strategy for the treatment of cancer. Drugs Fut 2010; 35:471-80.
39. Oroudjev E, Lopus M, Wilson L, Audette C, Provenzano C, Erickson H, Kovtun Y, Chari R, Jordan MA. Maytansinoid-antibody conjugates induce mitotic arrest by suppressing microtubule dynamic instability. Mol Cancer Ther 2010; 9:2700-13; PMID:20937595; http://dx.doi.org/10.1158/1535-7163.MCT-10-0645
40. Fuertes MA, Alonso C, Pérez JM. Biochemical modulation of Cisplatin mechanisms of action: enhancement of antitumor activity and circumvention of drug resistance. Chem Rev 2003; 103:645-62; PMID:12630848; http://dx.doi.org/10.1021/cr020010d
41. Haller J, Burgess R, Dawson D. Increased cytotoxicity of squamous cell carcinoma of the head and neck by combining cisplatin with VP-16 and ciprofloxacin. Laryngoscope 1993; 103:1081-3; PMID:8412441; http://dx.doi.org/ 10.1288/00005537-199310000-00001
42. Jekunen AP, Christen RD, Shalinsky DR, Howell SB. Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 1994; 69:299-306; PMID:7905279; http://dx.doi.org/10.1038/bjc.1994.55
43. Jordan MA, Wilson L. Microtubules as a target for anticancer drugs. Nat Rev Cancer 2004; 4:253-65; PMID:15057285; http://dx.doi.org/10.1038/nrc1317
44. York J, Wolpert-DeFilippes MK, Johns DG, Sethi VS. Binding of maytansinoids to tubulin. Biochem Pharmacol 1981; 30:3239-43; PMID:7317106; http://dx.doi.org/10.1016/0006-2952(81)90524-4
45. Smith A, Waibel R, Westera G, Martin A, Zimmerman AT, Stahel RA. Immunolocalisation and imaging of small cell cancer xenografts by the IgG2a monoclonal antibody SWA11. Br J Cancer 1989; 59:174-8; PMID:2539173; http://dx.doi.org/10.1038/bjc.1989.36
46. Widdison WC, Wilhelm SD, Cavanagh EE, Whiteman KR, Leece BA, Kovtun Y, Goldmacher VS, Xie H, Steeves RM, Lutz RJ, et al. Semisynthetic maytansine analogues for the targeted treatment of cancer. J Med Chem 2006; 49:4392-408; PMID:16821799; http://dx.doi.org/10.1021/jm060319f
47. Bissery MC, Guénard D, Guéritte-Voegelein F, Lavelle F. Experimental antitumor activity of taxotere (RP 56976, NSC 628503), a taxol analogue. Cancer Res 1991; 51:4845-52; PMID:1680023